Platelet-rich plasma (PRP) has proven to be a very safe therapeutic option in the treatment of tendon, muscle, bone, and cartilage injuries. Currently, several commercial separation systems are available for the preparation of PRP. The concentrations of blood components in PRP among these separation systems vary substantially.
Purpose:
To systematically review and evaluate the differences between the concentrations of blood components in PRP produced by various PRP separation systems.
Study Design:
Systematic review.
Methods:
MEDLINE/PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), and EMBASE were searched for studies that compared the concentrations of blood components and growth factors in PRP between various separation systems and studies that reported on the concentrations of blood components and growth factors of single separation systems. The primary outcomes were platelet count, leukocyte count, and concentration of growth factors (eg, platelet-derived growth factor–AB [PDGF-AB], transforming growth factor–β1 [TGF-β1], and vascular endothelial growth factor [VEGF]). Furthermore, the preparation protocols and prices of the systems were compared.
Results:
There were 1079 studies found, of which 19 studies were selected for inclusion in this review. The concentrations of platelets and leukocytes in PRP differed largely between, and to a lesser extent within, the studied PRP separation systems. Additionally, large differences both between and within the studied PRP separation systems were found for all the growth factors. Furthermore, preparation protocols and prices varied widely between systems.
Conclusion:
There is a large heterogeneity between PRP separation systems regarding concentrations of platelets, leukocytes, and growth factors in PRP. The choice for the most appropriate type of PRP should be based on the specific clinical field of application. As the ideal concentrations of blood components and growth factors for the specific fields of application are yet to be determined for most of the fields, future research should focus on which type of PRP is most suitable for the specific field.
AnituaE.Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants. 1999;14:529-535.
2.
AnituaEZalduendoMTroyaMPadillaSOriveG.Leukocyte inclusion within a platelet rich plasma-derived fibrin scaffold stimulates a more pro-inflammatory environment and alters fibrin properties. PLoS One. 2015;10(3):e0121713.
3.
AnituaEZalduendoMMAlkhraisatMHOriveG.Release kinetics of platelet-derived and plasma-derived growth factors from autologous plasma rich in growth factors. Ann Anat. 2013;195(5):461-466.
4.
AssirelliEFilardoGMarianiEet al. Effect of two different preparations of platelet-rich plasma on synoviocytes. Knee Surg Sports Traumatol Arthrosc. 2015;23(9):2690-2703.
5.
BraunHJKimHJChuCRDragooJL.The effect of platelet-rich plasma formulations and blood products on human synoviocytes: implications for intra-articular injury and therapy. Am J Sports Med. 2014;42(5):1204-1210.
6.
CarlsonNERoachRB.Platelet-rich plasma-clinical applications in dentistry. J Am Dent Assoc. 2002;133:1383-1386.
7.
CastilloTNPouliotMAKimHJet al. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med. 2011;39:266-271.
8.
CavalloCFilardoGMarianiEet al. Comparison of platelet-rich plasma formulations for cartilage healing: an in vitro study. J Bone Joint Surg Am. 2014;96(5):423-429.
9.
DavisVLAbukabdaABRadioNMet al. Platelet-rich preparations to improve healing, part II: platelet activation and enrichment, leukocyte inclusion, and other selection criteria. J Oral Implantol. 2014;40(4):511-521.
10.
DenapoliPMStilhanoRSInghamSJHanSWAbdallaRJ.Platelet-rich plasma in a murine model: leukocytes, growth factors, Flt-1, and muscle healing. Am J Sports Med. 2016;44(8):1962-1971.
11.
DhuratRSukeshM.Principles and methods of preparation of platelet-rich plasma: a review and author’s perspective. J Cutan Aesthet Surg. 2014;7(4):189-197.
12.
Dohan EhrenfestDMRasmussonLAlbrektssonT.Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27:158-167.
13.
DragooJLKorotkovaTWasterlainASPouliotMAKimHJGolishSR.Age-related changes of chondrogenic growth factors in platelet-rich plasma. Oper Tech Orthop. 2012;22(2):49-55.
14.
DupleyLCharalambousCP.Platelet-rich plasma injections as a treatment for refractory patellar tendinosis: a meta-analysis of randomised trials. Knee Surg Relat Res. 2017;29(3):165-171.
15.
EngebretsenLSteffenKAlsousouJet al. IOC consensus paper on the use of platelet-rich plasma in sports medicine. Br J Sports Med. 2010;44(15):1072-1081.
16.
EvansonJRGuytonMKOliverDLet al. Gender and age differences in growth factor concentrations from platelet-rich plasma in adults. Mil Med. 2014;179(7):799-805.
17.
EverhartJSColeDSojkaJHet al. Treatment options for patellar tendinopathy: a systematic review. Arthroscopy. 2017;33(4):861-872.
18.
EvertsPADevileeRJBrown MahoneyCet al. Exogenous application of platelet-leukocyte gel during open subacromial decompression contributes to improved patient outcome: a prospective randomized double-blind study. Eur Surg Res. 2008;40(2):203-210.
19.
FilardoGDi MatteoBKonEMerliGMarcacciM.Platelet-rich plasma in tendon-related disorders: results and indications [published online September24, 2016]. Knee Surg Sports Traumatol Arthrosc. doi:10.1007/s00167-016-4261-4.
20.
FitzpatrickJBulsaraMZhengMH.The effectiveness of platelet-rich plasma in the treatment of tendinopathy: a meta-analysis of randomized controlled clinical trials. Am J Sports Med. 2017;45(1):226-233.
21.
FosterTEPuskasBLMandelbaumBRGerhardtMBRodeoSA.Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 2009;37:2259-2272.
22.
GentilePCervelliV.Use of platelet-rich plasma in maxillofacial surgery. J Craniofac Surg. 2012;23(5):1580-1582.
23.
GosensTPeerboomsJCvan LaarWden OudstenBL.Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: a double-blind randomized controlled trial with 2-year follow-up. Am J Sports Med. 2011;39(6):1200-1208.
24.
HamiltonBTolJLKnezWChalabiH.Exercise and the platelet activator calcium chloride both influence the growth factor content of platelet-rich plasma (PRP): overlooked biochemical factors that could influence PRP treatment. Br J Sports Med. 2015;49(14):957-960.
25.
HowardDShepherdJHKewSJet al. Release of growth factors from a reinforced collagen GAG matrix supplemented with platelet rich plasma: influence on cultured human meniscal cells. J Orthop Res. 2014;32(2):273-278.
26.
KauxJFLe GoffCRenoufJet al. Comparison of the platelet concentrations obtained in platelet-rich plasma (PRP) between the GPS™ II and GPS™ III systems. Pathol Biol (Paris). 2011;59(5):275-277.
27.
KauxJFLe GoffCSeidelLet al. Comparative study of five techniques of preparation of platelet-rich plasma. Pathol Biol (Paris). 2011;59(3):157-160.
28.
KobayashiYSaitaYNishioHet al. Leukocyte concentration and composition in platelet-rich plasma (PRP) influences the growth factor and protease concentrations. J Orthop Sci. 2016;21(5):683-689.
29.
KushidaSKakudoNMorimotoNet al. Platelet and growth factor concentrations in activated platelet-rich plasma: a comparison of seven commercial separation systems. J Artif Organs. 2014;17(2):186-192.
30.
LeitnerGCGruberRNeumullerJet al. Platelet content and growth factor release in platelet-rich plasma: a comparison of four different systems. Vox Sang. 2006;91(2):135-139.
31.
LisiCPerottiCScudellerLet al. Treatment of knee osteoarthritis: platelet-derived growth factors vs. hyaluronic acid. A randomized controlled trial [published online August1, 2017]. Clin Rehabil. doi:10.1177/0269215517724193.
32.
MagalonJBaussetOSerratriceNet al. Characterization and comparison of 5 platelet-rich plasma preparations in a single-donor model. Arthroscopy. 2014;30(5):629-638.
MarxRE.Platelet-rich plasma (PRP): what is PRP and what is not PRP?Implant Dent. 2001;10:225-228.
35.
MarxRECarlsonEREichstaedtRMSchimmeleSRStraussJEGeorgeffKR.Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85:638-646.
36.
MazzoccaADMcCarthyMBChowaniecDMet al. Platelet-rich plasma differs according to preparation method and human variability. J Bone Joint Surg Am. 2012;94:308-316.
37.
MazzuccoLBalboVCattanaEGuaschinoRBorziniP.Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, RegenPRP-Kit, Plateltex and one manual procedure. Vox Sang. 2009;97(2):110-118.
38.
McCarrelTMMinasTFortierLA.Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg Am. 2012;94(19):e143(1-8).
39.
MeheuxCJMcCullochPCLintnerDMVarnerKEHarrisJD.Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a systematic review. Arthroscopy. 2016;32(3):495-505.
40.
MiBLiuGZhouWet al. Platelet rich plasma versus steroid on lateral epicondylitis: meta-analysis of randomized clinical trials. Phys Sportsmed. 2017;45(2):97-104.
41.
MishraAKSkrepnikNVEdwardsSGet al. Efficacy of platelet-rich plasma for chronic tennis elbow: a double-blind, prospective, multicenter, randomized controlled trial of 230 patients. Am J Sports Med. 2014;42(2):463-471.
42.
MlynarekRAKuhnAWBediA.Platelet-rich plasma (PRP) in orthopedic sports medicine. Am J Orthop (Belle Mead NJ). 2016;45(5):290-326.
43.
MolloyTWangYMurrellG.The roles of growth factors in tendon and ligament healing. Sports Med. 2003;33:381-394.
44.
MoojenDJEvertsPASchureRMet al. Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J Orthop Res. 2008;26:404-410.
45.
OginoYAyukawaYKukitaTKoyanoK.The contribution of platelet-derived growth factor, transforming growth factor-beta1, and insulin-like growth factor-I in platelet-rich plasma to the proliferation of osteoblast-like cells. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101(6):724-729.
46.
OhJHKimWParkKURohYH.Comparison of the cellular composition and cytokine-release kinetics of various platelet-rich plasma preparations. Am J Sports Med. 2015;43(12):3062-3070.
47.
PlachokovaASNikolidakisDMulderJJansenJACreugersNH.Effect of platelet-rich plasma on bone regeneration in dentistry: a systematic review. Clin Oral Implants Res. 2008;19(6):539-545.
48.
RibohJCSaltzmanBMYankeABFortierLColeBJ.Effect of leukocyte concentration on the efficacy of platelet-rich plasma in the treatment of knee osteoarthritis. Am J Sports Med. 2016;44(3):792-800.
49.
Rubio-AzpeitiaEBilbaoAMSánchezPDelgadoDAndiaI.The properties of 3 different plasma formulations and their effects on tendinopathic cells. Am J Sports Med. 2016;44(8):1952-1961.
50.
RussellRPApostolakosJHiroseTCoteMPMazzoccaAD.Variability of platelet-rich plasma preparations. Sports Med Arthrosc. 2013;21(4):186-190.
51.
ScharMODiaz-RomeroJKohlSZumsteinMANesicD.Platelet-rich concentrates differentially release growth factors and induce cell migration in vitro. Clin Orthop Relat Res. 2015;473(5):1635-1643.
52.
ShenLYuanTChenSXieXZhangC.The temporal effect of platelet-rich plasma on pain and physical function in the treatment of knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials. J Orthop Surg Res. 2017;12(1):16.
53.
SommelingCEHeynemanAHoeksemaHVerbelenJStillaertFBMonstreyS.The use of platelet-rich plasma in plastic surgery: a systematic review. J Plast Reconstr Aesthet Surg. 2013;66(3):301-311.
54.
SundmanEAColeBJFortierLA.Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med. 2011;39(10):2135-2140.
55.
WeibrichGKleisWKHafnerGet al. Comparison of platelet, leukocyte, and growth factor levels in point-of-care platelet-enriched plasma, prepared using a modified Curasan kit, with preparations received from a local blood bank. Clin Oral Implants Res. 2003;14:357-362.
56.
WeibrichGKleisWKHitzlerWEHafnerG.Comparison of the platelet concentrate collection system with the plasma-rich-in-growth-factors kit to produce platelet-rich plasma: a technical report. Int J Oral Maxillofac Implants. 2005;20(1):118-123.
57.
WeibrichGKleisWKStreckbeinPMoergelMHitzlerWEHafnerG.Comparison of point-of-care methods for preparation of platelet concentrate (platelet-rich plasma). Int J Oral Maxillofac Implants. 2012;27(4):762-769.
58.
WillitsKKanikiNBryantD.The use of platelet-rich plasma in orthopaedic injuries. Sports Med Arthrosc. 2013;21(4):225-230.
59.
YinWQiXZhangYet al. Advantages of pure platelet-rich plasma compared with leukocyte- and platelet-rich plasma in promoting repair of bone defects. J Transl Med. 2016;14:73.
60.
YinWJXuHTShengJGet al. Advantages of pure platelet-rich plasma compared with leukocyte- and platelet-rich plasma in treating rabbit knee osteoarthritis. Med Sci Monit. 2016;22:1280-1290.
61.
ZhangLChenSChangPet al. Harmful effects of leukocyte-rich platelet-rich plasma on rabbit tendon stem cells in vitro. Am J Sports Med. 2016;44(8):1941-1951.
62.
ZhouYZhangJWuHHoganMVWangJH.The differential effects of leukocyte-containing and pure platelet-rich plasma (PRP) on tendon stem/progenitor cells: implications of PRP application for the clinical treatment of tendon injuries. Stem Cell Res Ther. 2015;6:173.
63.
ZimmermannRArnoldDStrasserEet al. Sample preparation technique and white cell content influence the detectable levels of growth factors in platelet concentrates. Vox Sang. 2003;85:283-289.
64.
ZimmermannRJakubietzRJakubietzMet al. Different preparation methods to obtain platelet components as a source of growth factors for local application. Transfusion. 2001;41(10):1217-1224.
